Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
PerkinElmer operates as a diversified life sciences and diagnostics company serving pharmaceutical, biotech, clinical diagnostics, and applied markets globally. The company provides analytical instruments, reagents, informatics software, and services across two primary segments: Diagnostics (prenatal/newborn screening, infectious disease testing) and Life Sciences (drug discovery, food/environmental testing). Recent portfolio rationalization and moderate margins suggest a business in transition, with exposure to both recurring consumables revenue and cyclical capital equipment sales.
PerkinElmer employs a razor-razorblade model where capital equipment placements (instruments) generate recurring consumable, reagent, and service revenue streams. Diagnostics segment benefits from regulatory-mandated newborn screening programs in developed markets, providing stable revenue base. Life Sciences segment captures R&D spending from pharma/biotech customers, with pricing power derived from proprietary detection technologies and embedded customer workflows. Gross margins of 54.8% reflect mix of higher-margin consumables/software versus lower-margin instruments, with operating leverage constrained by R&D investment requirements (estimated 6-8% of revenue) and global service infrastructure costs.
Pharma/biotech R&D spending trends and drug development pipeline activity driving Life Sciences instrument and consumable demand
Clinical diagnostics volume trends, particularly newborn screening test volumes and adoption of expanded screening panels in emerging markets
Capital equipment order rates and backlog conversion, especially large instrument placements at pharmaceutical and academic research institutions
Margin expansion initiatives from portfolio optimization, manufacturing footprint rationalization, and shift toward higher-margin consumables/software
M&A activity and portfolio repositioning, as company has history of acquisitions and recent divestitures to focus core business
Technological disruption from next-generation sequencing and alternative diagnostic platforms potentially displacing traditional mass spectrometry and chromatography instruments in certain applications
Regulatory changes to newborn screening mandates or reimbursement rates in key markets (US, Europe, China) could impact Diagnostics segment stability
Consolidation among pharmaceutical customers and hospital systems increasing pricing pressure and reducing number of independent buying centers
Shift toward decentralized diagnostics and point-of-care testing reducing demand for centralized lab instrumentation
Intense competition from larger diversified players (Thermo Fisher Scientific, Danaher/Beckman Coulter, Agilent) with broader product portfolios and greater R&D resources
Specialized competitors in diagnostics (Roche Diagnostics, Abbott) and life sciences (Waters Corporation, Bruker) with deeper domain expertise in specific segments
Pricing pressure in mature instrument categories as technology commoditizes, requiring continuous innovation to maintain premium positioning
Moderate leverage at 0.48x debt/equity manageable but limits financial flexibility for large M&A or aggressive buybacks during downturn
Low 3.2% ROE suggests capital allocation challenges or portfolio drag from underperforming assets, indicating potential need for further restructuring
Free cash flow of $0.5B represents only 3.6% yield at current market cap, below peer average, constraining shareholder return capacity
moderate - Diagnostics segment (~45-50% of revenue) exhibits low cyclicality due to regulatory-mandated newborn screening and essential clinical testing, providing revenue floor. Life Sciences segment shows moderate cyclicality tied to pharmaceutical R&D budgets and academic research funding, which typically lag GDP by 6-12 months. Applied markets (food safety, environmental testing) demonstrate moderate sensitivity to industrial activity and regulatory enforcement cycles. Overall business less cyclical than pure capital equipment plays due to 40-45% recurring revenue base.
Rising rates create modest headwinds through two channels: (1) higher financing costs for customers purchasing capital equipment on credit terms, potentially extending sales cycles or reducing order sizes for $100K-$500K+ instrument systems; (2) valuation multiple compression as life sciences tools sector typically trades at premium multiples (18-25x EBITDA) that contract when risk-free rates rise. However, balance sheet impact limited with moderate 0.48x debt/equity ratio. Pharmaceutical customers generally less rate-sensitive given strong balance sheets, but academic/government labs face budget pressure in rising rate environments.
Minimal direct credit exposure as customer base consists primarily of investment-grade pharmaceutical companies, government-funded hospitals/labs, and academic institutions with low default risk. Working capital requirements moderate with 1.68x current ratio. Customer financing programs for instrument sales create modest credit exposure, but typically secured by equipment and spread across diversified customer base.
value - Current valuation at 4.0x P/S and 18.2x EV/EBITDA sits below historical life sciences tools sector averages (5-7x P/S, 22-28x EBITDA), attracting value investors betting on margin recovery and portfolio optimization. Negative recent returns (-16.6% 1-year, -19.8% 6-month) and declining net income (-10.8% YoY) suggest market skepticism around turnaround execution. Limited dividend yield and modest FCF yield (3.6%) reduce appeal to income investors. Quality-focused value investors may be attracted to diagnostics segment stability and recurring revenue base once restructuring completes.
moderate - Life sciences tools sector typically exhibits moderate volatility (beta 0.9-1.1 range) with drawdowns during economic uncertainty when pharma R&D budgets face scrutiny. Recent 19.8% six-month decline suggests elevated volatility during current transition period. Diagnostics segment provides downside protection while Life Sciences segment drives upside participation in pharma innovation cycles.